Read by QxMD icon Read

psoriasis vascular inflammation

Byung-Soo Kim, Won-Ku Lee, Kyoungjune Pak, Junhee Han, Gun-Wook Kim, Hoon-Soo Kim, Hyun-Chang Ko, Moon-Bum Kim, Seong-Jang Kim
BACKGROUND: Evidence suggests that psoriasis may be associated with metabolic syndrome and an increased risk of cardiovascular disease. OBJECTIVE: To determine whether ustekinumab reduces systemic and vascular inflammation associated with metabolic syndrome and cardiovascular disease, measured using18 F-fluorodeoxyglucose positron emission tomography/computed tomography (18 F-FDG PET/CT). METHODS: Patients with psoriasis and healthy controls underwent baseline18 F-FDG PET/CT imaging...
March 17, 2018: Journal of the American Academy of Dermatology
Kalpna Gupta, Ilkka T Harvima
Mast cells are best recognized for their role in allergy and anaphylaxis, but increasing evidence supports their role in neurogenic inflammation leading to pain and itch. Mast cells act as a "power house" by releasing algogenic and pruritogenic mediators, which initiate a reciprocal communication with specific nociceptors on sensory nerve fibers. Consequently, nerve fibers release inflammatory and vasoactive neuropeptides, which in turn activate mast cells in a feedback mechanism, thus promoting a vicious cycle of mast cell and nociceptor activation leading to neurogenic inflammation and pain/pruritus...
March 2018: Immunological Reviews
Ye-Hong Kuang, Yan Lu, Ying-Ke Liu, Li-Qiu Liao, Xing-Chen Zhou, Qun-Shi Qin, Xue-Kun Jia, Li-Sha Wu, Wu Zhu, Xiang Chen
Psoriasis is a chronic auto-immune inflammation disease with skin lesions and abnormal keratinocyte proliferation. Sunitinib, a multi-targeted tyrosine kinase inhibitor, is known to selectively inhibit several growth factor receptors, including vascular endothelial growth factor receptor, platelet-derived growth factor receptor and stem cell factor. It was reported that a patient with renal cell carcinoma (RCC) whose psoriatic lesion was resolved dramatically during treatment with Sunitinib, however, the mechanism is still unclear...
January 27, 2018: European Journal of Pharmacology
Yvonne Baumer, Qimin Ng, Gregory E Sanda, Amit K Dey, Heather L Teague, Alexander V Sorokin, Pradeep K Dagur, Joanna I Silverman, Charlotte L Harrington, Justin A Rodante, Shawn M Rose, Nevin J Varghese, Agastya D Belur, Aditya Goyal, Joel M Gelfand, Danielle A Springer, Christopher Ke Bleck, Crystal L Thomas, Zu-Xi Yu, Mårten Cg Winge, Howard S Kruth, M Peter Marinkovich, Aditya A Joshi, Martin P Playford, Nehal N Mehta
Inflammation is critical to atherogenesis. Psoriasis is a chronic inflammatory skin disease that accelerates atherosclerosis in humans and provides a compelling model to understand potential pathways linking these diseases. A murine model capturing the vascular and metabolic diseases in psoriasis would accelerate our understanding and provide a platform to test emerging therapies. We aimed to characterize a new murine model of skin inflammation (Rac1V12) from a cardiovascular standpoint to identify novel atherosclerotic signaling pathways modulated in chronic skin inflammation...
January 11, 2018: JCI Insight
Yuan Wang, Ying Mao, Junfeng Zhang, Gang Shi, Lin Cheng, Yi Lin, Yiming Li, Xiaomei Zhang, Yujing Zhang, Xiaolei Chen, Jie Deng, Xiaolan Su, Lei Dai, Yang Yang, Shuang Zhang, Dechao Yu, Yuquan Wei, Hongxin Deng
Interleukin-35 (IL-35), a member of the IL-12 family, functions as a new anti-inflammatory factor involved in arthritis, psoriasis, inflammatory bowel disease (IBD) and other immune diseases. Although IL-35 can significantly prevent the development of inflammation in many diseases, there have been no early studies accounting for the role of IL-35 recombinant protein in IBD and psoriasis. In this study, we assessed the therapeutic potential of IL-35 recombinant protein in three well-known mouse models: the dextransulfate sodium (DSS)-induced colitis mouse model, the keratin14 (K14)-vascular endothelial growth factor A (VEGF-A)-transgenic (Tg) psoriasis mouse model and the imiquimod (IMQ)-induced psoriasis mouse model...
February 2018: Journal of Cellular and Molecular Medicine
Margery A Connelly, James D Otvos, Irina Shalaurova, Martin P Playford, Nehal N Mehta
BACKGROUND: GlycA is a novel spectroscopic marker of systemic inflammation with low intra-individual variability and other attributes favoring its clinical use in patients with chronic inflammatory and autoimmune diseases. GlycA is unique in its composite nature, reflecting both increased glycan complexity and circulating acute phase protein levels during local and systemic inflammation. Recent studies of GlycA from cross-sectional, observational and interventional studies have been highly informative, demonstrating that GlycA is elevated in acute and chronic inflammation, predicts death in healthy individuals and is associated with disease severity in patients with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis and lupus...
October 27, 2017: Journal of Translational Medicine
Nehal N Mehta, Heather L Teague, William R Swindell, Yvonne Baumer, Nicole L Ward, Xianying Xing, Brooke Baugous, Andrew Johnston, Aditya A Joshi, Joanna Silverman, Drew H Barnes, Liza Wolterink, Rajan P Nair, Philip E Stuart, Martin Playford, John J Voorhees, Mrinal K Sarkar, James T Elder, Katherine Gallagher, Santhi K Ganesh, Johann E Gudjonsson
Chronic inflammation is a critical component of atherogenesis, however, reliable human translational models aimed at characterizing these mechanisms are lacking. Psoriasis, a chronic inflammatory skin disease associated with increased susceptibility to atherosclerosis, provides a clinical human model that can be utilized to investigate the links between chronic inflammation and atherosclerosis development. We sought to investigate key biological processes in psoriasis skin and human vascular tissue to identify biological components that may promote atherosclerosis in chronic inflammatory conditions...
October 23, 2017: Scientific Reports
Joshua P Rivers, Tiffany M Powell-Wiley, Amit K Dey, Justin A Rodante, Jonathan H Chung, Aditya A Joshi, Balaji Natarajan, Aparna P Sajja, Abhishek Chaturvedi, Anshuma Rana, Charlotte L Harrington, Heather L Teague, Benjamin N Lockshin, Mark A Ahlman, Jianhua Yao, Martin P Playford, Joel M Gelfand, Nehal N Mehta
OBJECTIVES: We sought to examine the relationship between visceral adipose tissue (VAT) and vascular inflammation (VI) by (18)fluorodeoxyglucose ((18)FDG) positron-emission tomography (PET)/computed tomography (CT) in psoriasis (PSO). Furthermore, we evaluated whether treatment of PSO modulated VAT and VI. BACKGROUND: PSO, a chronic inflammatory skin disease, is associated with VI by (18)FDG PET/CT and increased cardiometabolic risk including adipose tissue dysregulation...
October 14, 2017: JACC. Cardiovascular Imaging
Juan-Hua Liu, Hui-Hui Wu, Yu-Kun Zhao, Fang Wang, Qian Gao, Di-Qing Luo
Background Psoriasis is a chronic inflammatory skin disorder of unknown etiology. Increasing evidence suggests that psoriasis is probably an angiogenesis-dependent disease. Thalidomide has been reported being able to inhibit the effects of fibroblast growth factor 2 and vascular endothelial growth factor (VEGF), and inhibit tumour necrosis factor-alpha synthesis, and suppress tumour necrosis factor-induced nuclear factor-kappa B activation in Jurkat cells, resulting in suppression of proliferation inflammation, angiogenesis, and the immune system, which are related to the pathogenesis of psoriasis...
October 4, 2017: Current Vascular Pharmacology
Felix Locker, Silvia Vidali, Barbara S Holub, Julia Stockinger, Susanne M Brunner, Sabine Ebner, Andreas Koller, Andrea Trost, Herbert A Reitsamer, David Schwarzenbacher, Roland Lang, Barbara Kofler
The neuropeptide galanin is distributed in the central and peripheral nervous systems and in non-neuronal peripheral organs, including the skin. Galanin acts via three G protein-coupled receptors which, except galanin receptor 1, are expressed in various skin structures. The galanin system has been associated with inflammatory processes of the skin and of several other organs. Psoriasis is an inflammatory skin disease with increased neo-vascularization, keratinocyte hyperproliferation, a pro-inflammatory cytokine milieu, and immune cell infiltration...
August 24, 2017: Journal of Investigative Dermatology
Alexander Egeberg, Lone Skov, Aditya A Joshi, Lotus Mallbris, Gunnar H Gislason, Jashin J Wu, Justin Rodante, Joseph B Lerman, Mark A Ahlman, Joel M Gelfand, Nehal N Mehta
BACKGROUND: Psoriasis is associated with risk of cardiovascular (CV) disease (CVD) and a major adverse CV event (MACE). Whether psoriasis duration affects risk of vascular inflammation and MACEs has not been well characterized. OBJECTIVES: We utilized two resources to understand the effect of psoriasis duration on vascular disease and CV events: (1) a human imaging study and (2) a population-based study of CVD events. METHODS: First, patients with psoriasis (N = 190) underwent fludeoxyglucose F 18 positron emission tomography/computed tomography (duration effect reported as a β-coefficient)...
October 2017: Journal of the American Academy of Dermatology
Maeve Lynch, Tomas Ahern, Cheryl M Sweeney, Anna Malara, Anne-Marie Tobin, Donal O'Shea, Brian Kirby
Adipokines are secreted by white adipose tissue, an active endocrine organ, and play a role in the regulation of metabolic functions such as lipid metabolism, inflammation, and vascular homeostasis. Adipokines are secreted in excess in obesity and contribute to the development of associated comorbidities such as metabolic syndrome and atherosclerosis. Psoriasis, a chronic immune-mediated skin disease, is associated with obesity and increased cardiovascular risk. Understanding the role of adipokines in psoriasis may in part explain the association between psoriasis and cardiovascular disease...
November 2017: International Journal of Dermatology
Agnes Szentpetery, Eric Heffernan, Martina Gogarty, Lisa Mellerick, Janet McCormack, Muhammad Haroon, Musaab Elmamoun, Phil Gallagher, Genevieve Kelly, Aurelie Fabre, Brian Kirby, Oliver FitzGerald
BACKGROUND: The aim was to study changes in immunohistochemical expression markers of synovial and skin inflammation, clinical outcomes and magnetic resonance imaging (MRI) scores with abatacept treatment in patients with psoriatic arthritis (PsA). METHODS: Biological-treatment-naïve PsA patients with active disease including synovitis of a knee were enrolled in this single-centre, crossover study. Patients were randomised to receive intravenous abatacept 3 mg/kg of body weight or placebo infusion on day 1, 15 and 29; thereafter abatacept 10 mg/kg of body weight was administered every 28 days for 5 months...
July 5, 2017: Arthritis Research & Therapy
Robert Bissonnette, François Harel, James G Krueger, Marie-Claude Guertin, Malorie Chabot-Blanchet, Juana Gonzalez, Catherine Maari, Isabelle Delorme, Charles W Lynde, Jean-Claude Tardif
No abstract text is available yet for this article.
October 2017: Journal of Investigative Dermatology
Kasper Fjellhaugen Hjuler, Lars Christian Gormsen, Lars Iversen
No abstract text is available yet for this article.
October 2017: Journal of Investigative Dermatology
Reiko Arita, Motoko Kawashima, Masataka Ito, Kazuo Tsubota
BACKGROUND: Hyperkeratinization is a major cause of obstructive meibomian gland dysfunction (oMGD) and results in degenerative gland dilation and atrophy without inflammation. Ointment containing 1,25-dihydroxy-22-oxavitamin D3 (maxacalcitol), a noncalcemic analog of the active form of vitamin D3, is applied for the treatment of hyperkeratotic cutaneous conditions such as psoriasis and ichtyosis because it suppresses the proliferation and promotes the differentiation of keratinocytes through interaction with the vitamin D receptor...
June 7, 2017: BMC Ophthalmology
Amit K Dey, Aditya A Joshi, Abhishek Chaturvedi, Joseph B Lerman, Tsion M Aberra, Justin A Rodante, Heather L Teague, Charlotte L Harrington, Joshua P Rivers, Jonathan H Chung, Mohammad Tarek Kabbany, Balaji Natarajan, Joanna I Silverman, Qimin Ng, Gregory E Sanda, Alexander V Sorokin, Yvonne Baumer, Emily Gerson, Ronald B Prussick, Alison Ehrlich, Lawrence J Green, Benjamin N Lockshin, Mark A Ahlman, Martin P Playford, Joel M Gelfand, Nehal N Mehta
Importance: Inflammation is critical in the development of atherosclerosis. Psoriasis is a chronic inflammatory skin disease that is associated with increased vascular inflammation by 18fluorodeoxyglucose positron emission tomography/computed tomography in vivo and future cardiovascular events. It provides a human model to understand the effect of treating inflammation in a target organ (eg, the skin) on vascular diseases. Objective: To investigate the association between change in skin disease severity and change in vascular inflammation at 1 year and to characterize the impact of 1 year of anti-tumor necrosis factor therapy on vascular inflammation...
September 1, 2017: JAMA Cardiology
K A Rubina, V Yu Sysoeva, E I Zagorujko, Z I Tsokolaeva, M I Kurdina, Ye V Parfyonova, V A Tkachuk
There is substantial evidence implicating the urokinase system in tissue remodeling during neo-vascularization, inflammation, tumor invasion, and metastasis. Regulated degradation of the extracellular matrix at the leading edge of migrating cells, mediated by uPA and uPAR, is required for tissue remodeling, invasiveness, and angiogenesis. Psoriasis and basal cell carcinoma (BCC) are the most common skin diseases. Pathogenesis of both of them is associated with keratinocyte hyperproliferation, inflammatory cell migration, and angiogenesis-processes in which the plasminogen system (uPA, uPAR, tPA, and PAI-1) plays a crucial role...
August 2017: Archives of Dermatological Research
H J A Hunter
No abstract text is available yet for this article.
April 2017: British Journal of Dermatology
Robert Bissonnette, François Harel, James G Krueger, Marie-Claude Guertin, Malorie Chabot-Blanchet, Juana Gonzalez, Catherine Maari, Isabelle Delorme, Charles W Lynde, Jean-Claude Tardif
Vascular inflammation is increased in patients with psoriasis. This randomized, double-blind, multicenter study evaluated the effects of tumor necrosis factor-α antagonist adalimumab on vascular inflammation in patients with psoriasis. A total of 107 patients were randomized (1:1) to receive adalimumab for 52 weeks or placebo for 16 weeks followed by adalimumab for 52 weeks. Vascular inflammation was assessed with positron emission tomography-computed tomography. There were no differences in the change from baseline in vessel wall target-to-background ratio (TBR) from the ascending aorta (primary endpoint) (adalimumab: TBR = 0...
August 2017: Journal of Investigative Dermatology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"